Melanie Dispenza, MD, PhD

Dr. Dispenza evaluates and treats adults at the Johns Hopkins Asthma & Allergy Center located on the Bayview campus. Her clinical interests include mastocytosis and anaphylaxis. She is an active member of the American Initiative in Mast Cell Diseases.  Additionally, as co-director for the Johns Hopkins Center for Anaphylaxis and Drug Hypersensitivity, her research focuses on IgE-mediated mechanisms of allergies and novel strategies for the diagnosis, prevention, and treatment of anaphylaxis.

View all trials by this principal investigator.

B Arce, NM Vilela, KA Sokol, S Alvarez-Arango, L Iacobelli, ET Oliver, D Croote, BS Bochner, DW MacGlashan, Jr., MC Dispenza.  The Bruton’s tyrosine kinase inhibitor acalabrutinib aborts ongoing acute food-induced anaphylactic reactions in humanized mice.  Epub 2025 Jul 17.  PMID: 40683570. 

RV Suresh, C Dunnam, D Vaidya, RA Wood, BS Bochner, DW MacGlashan, Jr., MC Dispenza.  A phase 2 study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis.  Journal of Clinical Investigation. 2023. August;133(16):e172335.  PMID 37384412.

MC Dispenza, RA Krier-Burris, KD Chhiba, BJ Undem, PA Robida, BS Bochner.  Bruton’s tyrosine kinase inhibition effectively protects against IgE-mediated anaphylaxis.  Journal of Clinical Investigation.  2020.  Sept;130(9): 4759-4770.  PMID: 32484802.  

MC Dispenza, JA Pongracic, AM Singh, BS Bochner.  Short Term Ibrutinib Therapy Suppresses Skin Test Responses and Eliminates IgE-Mediated Basophil Activation in Adults with Peanut or Tree Nut Allergy.  Journal of Allergy and Clinical Immunology.  2018.  May;141(5): 1914-1916.  PMID: 29360526.